OpenBench and Tavros Therapeutics Announce Collaboration to Pursue First-in-class Cancer Target

DURHAM, N.C. and SAN FRANCISCO: DURHAM, N.C. and SAN FRANCISCO, Dec. 2, 2021 /PRNewswire/ -- Tavros Therapeutics, a privately held biotechnology company discovering first-in-class cancer therapies, and OpenBench, an emerging leader in AI-enabled small molecule discovery, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an...

Click to view original post